Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Interleukin-4 modulates type I interferon to augment anti-tumour immunity [scRNA-Seq]

ABSTRACT: Interleukin-4 modulates type I interferon to augment anti-tumour immunity [scRNA-Seq]

PROVIDER: PRJNA1224250 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32360311_1.fastq.gz	Fastqsanger.gz
	SRR32360311_2.fastq.gz	Fastqsanger.gz
	SRR32360312_1.fastq.gz	Fastqsanger.gz
	SRR32360312_2.fastq.gz	Fastqsanger.gz
	SRR32360313_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 144

Similar Datasets

Interleukin-4 modulates type I interferon to augment anti-tumour immunity

Project description:Interleukin-4 modulates type I interferon to augment anti-tumour immunity

| PRJNA1224251 | ENA

Interleukin-4 modulates type I interferon to augment anti-tumour immunity

Project description:Despite advances in immunotherapy, metastatic melanoma remains a significant therapeutic challenge due to the complexity of the tumour microenvironment. Intratumoural type I interferon (IFN-I) has long been associated with improved clinical outcomes. However, several IFN-I subtypes can also paradoxically promote tumour growth in some contexts. We investigated this further by engineering murine B16 melanoma cells to overexpress various IFN-I subtypes, where a spectrum of outcomes was observed. Characterisation of these tumours by RNA-sequencing revealed a tumour immune phenotype, where potent IFN-I signalling concomitant with diminished type 2 inflammation failed to confer durable tumour control. T cell-mediated rejection of these tumours was restored by introducing interleukin (IL)-4 into the tumour microenvironment, either through ectopic expression or in a pre-clinical adoptive T cell therapy model. Collectively, our findings highlight the IFN-I/IL-4 axis in promoting anti-tumour immunity, which could be harnessed to target and stratify solid tumours that are non-responsive to frontline therapies.

2025-02-18 | GSE289722 | GEO

Interleukin-4 modulates type I interferon to augment anti-tumour immunity [scRNA-Seq]

2025-02-18 | GSE289723 | GEO

Interleukin-10 causes interferon-γ-dependent emergency myelopoiesis

Project description:Interleukin-10 causes interferon-γ-dependent emergency myelopoiesis

| PRJNA613303 | ENA

Interleukin-10 causes interferon γ-dependent emergency myelopoiesis

Project description:Interleukin-10 causes interferon γ-dependent emergency myelopoiesis

| PRJNA721937 | ENA

Interleukin-4 receptor signaling modulates neuronal network activity

Project description:Interleukin-4 receptor signaling modulates neuronal network activity

| PRJNA825260 | ENA

Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunity [RNA-seq]

Project description:Therapies that enhance anti-tumour immunity have dramatically changed the natural history of a range of cancers. Consequently, leveraging non-overlapping mechanisms to further increase the immunogenicity of cancer cells remains a major priority. Here, using a novel inhibitor of the RNA methyltransferase, METTL3, we demonstrate that enzymatic inhibition and a global decrease in N6-methyladenosine (m6A) results in double stranded RNA formation and a profound cell-intrinsic interferon response. By monitoring nascent mRNA, we show that the downstream induction of interferon stimulated genes (ISG) is coupled to a global increase in mRNA stability due to decreased m6A. One of the primary sequelae of this process is an increased expression and stability of genes associated with antigen presentation via MHC-I3. With unbiased global CRISPR screens we demonstrate that components of dsRNA sensing and interferon signalling are the primary mediators that potentiate T-cell killing of cancer cells following METTL3 inhibition. As PDL1, a key immune checkpoint, is also induced by interferon3, we show in a range of immunocompetent mouse models that whilst METTL3 inhibition alone is equally efficacious to anti-PD1 therapy, the combination has far greater pre-clinical activity. Importantly, using SPLINTR barcoding4, we demonstrate at single clone resolution that anti-PD1 and METTL3 inhibition target distinct malignant clones and the combination of these therapies augment anti-tumour immunity to overcome clones insensitive to the single agents. Together these data provide the molecular and pre-clinical rationale for employing METTL3 inhibitors to promote anti-tumour immunity in the clinical setting.

2023-10-12 | GSE217920 | GEO

Interleukin-4 receptor signaling modulates neuronal network activity [mouse]

Project description:Interleukin-4 receptor signaling modulates neuronal network activity [mouse]

| PRJNA825385 | ENA

Human islets treated with alpha-difluoromethylornithine in combination with interferon-gamma and interleukin-beta

Project description:Proteomic data of human islets treated for 24h with alpha-difluoromethylornithine in combination with interferon-gamma and interleukin-beta; 6 biological replicates. Samples were digested with trypsin, then analyzed by LC-DIA-MS. Data was searched with FragPipe/DIA-NN.

2023-03-07 | MSV000091431 | MassIVE

Investigation of the anti-tumour properties of interferon epsilon in high grade serous ovarian cancer in vivo.

Project description:This experiment is part of a larger study examining the anti-tumour properties of interferon epsilon in ovarian cancer. The goal of this experiment was to test the direct effects of interferon epsilon and interferon beta on human ovarian tumours in vivo, using patient derived xenografts (PDX) in immunocompromised (NSG) mice.

2023-03-28 | GSE201337 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data